Dose determination for molecularly targeted therapies: Much Ado About Nothing

被引：0

作者：

Tolcher, Anthony ^{[1
]}

机构：

[1] START, Clin Res, 4383 Med Dr,Suite 4021, San Antonio, TX 78229 USA

来源：

CANCER | 2017年 / 123卷 / 08期

关键词：

CELL LUNG-CANCER; PHASE-I; TRIAL; INHIBITOR; GEFITINIB; SAFETY; ZD1839;

D O I：

10.1002/cncr.30584

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Literature reviews and meta-analyses of phase 1 studies are particularly difficult to perform and rarely draw useful conclusions due to the small size of individual studies and the varied populations. With the low rate of success in oncology drug development, the focus should turn to improving the efficiency of phase 1 studies. See also pages 1409-15.

引用

页码：1298 / 1300

页数：3

共 10 条

[1] Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110
[2] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
Baselga, J
Rischin, D
Ranson, M
Calvert, H
Raymond, E
Kieback, DG
Kaye, SB
Gianni, L
Harris, A
Bjork, T
Averbuch, SD
Feyereislova, A
Swaisland, H
Rojo, F
Albanell, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302
[3] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
Fukuoka, M
Yano, S
Giaccone, G
Tamura, T
Nakagawa, K
Douillard, JY
Nishiwaki, Y
Vansteenkiste, J
Kudoh, S
Rischin, D
Eek, R
Horai, T
Noda, K
Takata, I
Smit, E
Averbuch, S
Macleod, A
Feyereislova, A
Dong, RP
Baselga, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
[4] Determinants of the recommended phase 2 dose of molecular targeted agents
Hansen, Aaron R.
Cook, Natalie
Amir, Eitan
Siu, Lillian L.
Razak, Albiruni Ryan Abdul
[J]. CANCER, 2017, 123 (08) : 1409 - 1415
[5] Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
Jain, Rajul K.
Lee, J. Jack
Hong, David
Markman, Maurie
Gong, Jing
Naing, Aung
Wheler, Jennifer
Kurzrock, Razelle
[J]. CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1289 - 1297
[6] Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases:: Results from two phase I studies
Morgan, B
Thomas, AL
Drevs, J
Hennig, J
Buchert, M
Jivan, A
Horsfield, MA
Mross, K
Ball, HA
Lee, L
Mietlowski, W
Fuxius, S
Unger, C
O'Byrne, K
Henry, A
Cherryman, GR
Laurent, D
Dugan, M
Marmé, D
Steward, WP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 3955 - 3964
[7] Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials
Sweis, Randy F.
Drazer, Michael W.
Ratain, Mark J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04) : 369 - +
[8] Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer
Thomas, AL
Morgan, B
Horsfield, MA
Higginson, A
Kay, A
Lee, L
Masson, E
Puccio-Pick, M
Laurent, D
Steward, WP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4162 - 4171
[9] Wang S., 2016, NY TIMES, pA23
[10] Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
Zhang, Li
Ma, Shenglin
Song, Xiangqun
Han, Baohui
Cheng, Ying
Huang, Cheng
Yang, Shujun
Liu, Xiaoqing
Liu, Yunpeng
Lu, Shun
Wang, Jie
Zhang, Shucai
Zhou, Caicun
Zhang, Xiangwei
Hayashi, Nobuya
Wang, Mengzhao
[J]. LANCET ONCOLOGY, 2012, 13 (05) : 466 - 475

← 1 →